BioVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioVie Inc. on April 6, 2023. The report addresses Item 8.01 (Other Events) regarding updates to the company's Controlled Equity Offering SM Sales Agreement dated August 31, 2022.
Key Financial Metrics
The filing provides specific data regarding the equity offering program as of April 3, 2023:
- Total Net Proceeds: $48.8 million
- Shares Issued: 7,391,228 shares of Class A common stock
- Commissions and Expenses: Approximately $1.7 million
- Remaining Offering Capacity: The agreement allows for an aggregate offering price of $17.5 million under the current prospectus supplement.
The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or general liquidity metrics beyond the proceeds from this specific offering.
Material Changes
On April 6, 2023, BioVie Inc. and B. Riley Securities, Inc. ("BRS") mutually agreed to terminate BRS's role as a sales agent under the Sales Agreement. Cantor Fitzgerald & Co. remains the sole sales agent. Additionally, the company filed a new prospectus supplement to continue offering shares under the existing registration statement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers regarding the validity of the securities offer. The document notes that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful.
Key Facts for Investor Verification
- Verify the current status of the Sales Agreement with Cantor Fitzgerald & Co. following the termination of BRS.
- Confirm the total number of shares outstanding post-issuance of the 7,391,228 shares mentioned.
- Review the effective registration statement (No. 333-252386) for the full terms of the $17.5 million offering capacity.
- Check subsequent filings for any additional sales made under the agreement after April 3, 2023.